ASCO: Drug combination shows significant superiority in relapsed or refractory multiple myeloma
Researchers report that adding belantamab mafodotin to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma is more effective at slowing disease progression or death… read more.